Standout Papers

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients wit... 2018 2026 2020 2023 264
  1. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia (2018)
    Piers Blombery, Mary Ann Anderson et al. Cancer Discovery
  2. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma (2018)
    Constantine S. Tam, Mary Ann Anderson et al. New England Journal of Medicine

Immediate Impact

4 from Science/Nature 53 standout
Sub-graph 1 of 22

Citing Papers

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2025 Standout
Cell death
2024 Standout
3 intermediate papers

Works of David Westerman being referenced

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
2018 Standout
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
2016
and 6 more

Author Peers

Author Last Decade Papers Cites
David Westerman 1391 1351 712 753 122 2.7k
E Montserrat 1374 1738 758 1006 96 3.0k
David S. Viswanatha 924 1724 1107 1109 127 3.5k
B Desablens 1210 1412 825 741 90 2.6k
Judith Dierlamm 1235 1793 809 1255 109 4.0k
Francesco Lauria 1609 1071 896 997 103 2.9k
Aspasia Stamatoullas 1174 1711 1347 1297 126 3.6k
Barry I. Samuels 728 1482 500 1309 68 2.7k
Achille Ambrosetti 1315 1506 786 702 66 2.8k
Nishitha Reddy 962 1358 498 990 112 2.2k
Mark Hertzberg 870 1445 1113 1645 164 3.4k

All Works

Loading papers...

Rankless by CCL
2026